Vertex Pharmaceutic (VRTX) Stock Price, Quote & News

Company Profile

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for peo...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 341 6100

Website: www.vrtx.com

Address:

50 Northern Avenue, Boston, United States

MarketPulsee Jul. 20 at 10:51 PM

25 High-Quality Stocks With The Strongest Operating Margins Strong operating margins often signal pricing power, efficiency, and durable competitive advantages. Top 25: $ANET — 42.7% $KLAC — 41.2% $META — 40.6% $HOOD — 38.5% $VRTX — 38.1% Quality screen: • Positive net income margin • Revenue & EPS growth >10% over next 3 years • Altman Z-Score >3 • Market cap >$10B High margins alone don’t make a stock a buy, but they often reveal companies with strong competitive advantages. Which names are in your portfolio? Any additions? DYOR. Not financial advice.

0 · Reply

abman54 Jul. 20 at 6:43 PM

$VRTX now why is it selling?

0 · Reply

SmartMoneyRadar Jul. 19 at 11:16 PM

The Future Investors presents the 25 quality stocks with the strongest operating margins in the market today 📈 Final part of the list: （Part 5） 2️⃣1️⃣ $ANET — 42.7% 2️⃣2️⃣ $KLAC — 41.2% 2️⃣3️⃣ $META — 40.6% 2️⃣4️⃣ $HOOD — 38.5% 2️⃣5️⃣ $VRTX — 38.1% Quality Criteria: ✅ Net Income Margin > 0% ✅ Revenue & EPS growth next 3Y > 10% ✅ Altman Z Score > 3 ✅ Market Cap > $10B Strong operating margins combined with healthy growth and financial strength can highlight companies with durable business models. Which of these quality stocks do you own? 👇 Investing doesn’t have to be complicated. Just listen to the smart money. Follow for more.

0 · Reply

Makingmillions192 Jul. 19 at 7:10 PM

$LEXX Trend reversal confirmation “Let’s jump on our white horses and go for a bullish ride. Today’s candlestick has a white body and its close is above the confirmation level. The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. The trend is also bullish and perhaps it is the right time to participate in bullish fervor. The market is signaling a potential new profit opportunity. Capitalize on this bullish opportunity without hesitation.” Melt up until data drops in Aug 🌋 💰 🧨 $SLS $RANI $VRTX $EDSA

1 · Reply

Zeestallion Jul. 17 at 7:18 PM

$VIVS just waiting to see when the market sees what I see. Top pharmaceutical company Eil Lilly. TRILLION DOLLAR company invested into this.$BEAM $PACB $JSPR $VRTX

2 · Reply

svertical1 Jul. 17 at 4:25 PM

$VRTX Great interview! CF Foundation- if only other disease specific foundations were as effective!

0 · Reply

DidYouReadThis Jul. 17 at 4:07 PM

$VRTX $SNY $GSK $MRNA

0 · Reply

svertical1 Jul. 17 at 2:06 PM

$VRTX If you know you know! WS has not even begun calculating povetacicept (pove) impact, ignoring strong best-in-class or highly competitive candidate in several of these indications: •IgA Nephropathy (IgAN) •Lupus Nephritis (LN) and ANCA-Associated Vasculitis (AAV) •Generalized Myasthenia Gravis Most well rounded pipe in biotech!

0 · Reply

biotech Jul. 17 at 11:54 AM

MONDAY $SGMO stalking horse deadline 🚨: another stalking horse bid for ie NAV1.7 for $50M from ie $VRTX would make $SGMO PPS jump some 300%

1 · Reply

StockConsultant Jul. 17 at 3:51 AM

A good day for stocks $BLDR $DBI $HALO $SPG and $VRTX rallying off the support areas, from Stocks to Watch at https://stockconsultant.com/?HALO

0 · Reply

How to Ride the $2.6 Trillion Merger Boom With High-Growth Stocks

CRNX VRTX

Jul 7, 2026, 4:00 PM EDT - 13 days ago

Market Cap	123.26B
Revenue (ttm)	12.00B
Net Income (ttm)	3.95B
EPS (ttm)	N/A
PE Ratio	28.90
Forward PE	28.58
Profit Margin	32.94%
Debt to Equity Ratio	0.00

Volume	1,101,700
Avg Vol	1,597,554
Day's Range	N/A - N/A
Shares Out	253.81M
Stochastic %K	19%
Beta	0.29
Analysts	Strong Sell
Price Target	$555.30